CCNE2 Antibody

1. the molecular mechanism of trastuzumab action in BT474 cell line may be regulated by miR-26a and miR-30b and CCNE2 overexpression might play an important role in acquired trastuzumab resistance in HER2+ breast cancer. PMID:28120942
2. Knockdown of CCNE2 promoted MCF7 cell apoptosis and G2-stage cell cycle arrest. PMID:30157476
3. Combinatorial PX-866 and Raloxifene Decrease Rb Phosphorylation, Cyclin E2 Transcription, and Proliferation of MCF-7 Breast Cancer Cells PMID:26660119
4. The results suggest that miR30a may function as a novel tumor suppressor in CRPC. Its antioncogenic activity may occur by the reduced expression of a distinct cell cycle protein, CCNE2. PMID:27431942
5. Overexpression of cyclin E2 is an early event in gastric carcinogenesis. PMID:27034264
6. Survivin and cyclin E2 genes expression may have clinical relevance and can be considered as molecular risk factors for AL. Also they may be useful as predictive markers for treatment outcome in leukemic patients. PMID:26600399
7. miR-26a regulated mouse hepatocyte proliferation by directly targeting the 3' untranslated regions of cyclin D2/cyclin E2. PMID:26818545
8. In breast cancer patients, high levels of HMGA1 and CCNE2 expression are associated with the YAP/TAZ signature. PMID:26265440
9. data suggests the potential role of monomorphic morphology, high cyclin E2 and Ki67 expression as adverse prognostic factors for TNKLPD PMID:25475054
10. miR-144-5p functions as tumour suppressor in BC cells. CCNE1 and CCNE2 were directly regulated by miR-144-5p and might be good prognostic markers for survival of bladder cancer patients PMID:26057453
11. Our study shows miR-25 is overexpressed in small cell lung cancer and acting as oncogenic regulator by regulating cyclin E2. PMID:25550809
12. Results suggest that the miR-30d-5p/CCNE2 axis may contribute to NSCLC cell proliferation and motility. PMID:25843294
13. Data indicate that miR-26a overexpression inhibited pancreatic cancer cell growth by the downregulation of cyclin E2 expression. PMID:24116110
14. In cancer cells Fbw7, fails to effectively target cyclin E2 for proteosomal degradation. PMID:23324394
15. Cyclin E2 induction of genomic instability by a mechanism distinct from cyclin E1 indicates that these two proteins have unique functions in a cancer setting. PMID:23324395
16. protein and mRNA expressions of Cyclin E2 in nasopharyngeal carcinoma PMID:22394640
17. Tamoxifen resistant tumors displayed enriched expression of genes related to cell cycle and proliferation, as well as elevated activity of E2F transcription factors. PMID:21789246
18. expression is deregulated in primary breast tumors PMID:12466974
19. The CCNE2 qualify as independent prognostic markers for lymph node-negative breast cancer patients. PMID:16740753
20. Since SCF(Fbxw7/hCdc4) is functionally inactivated in several cancer types, alteration of this molecular pathway could contribute to the deregulation of cyclin E2 in tumorigenesis. PMID:19084516
21. A hypothetical model whereby PTEN loss upregulates cell cycle genes such as cdc6 and cyclin E2 that in turn promote metastatic colonization at distant sites. PMID:19107233
22. Data indicate that cyclin E2-Cdk2 activation by estrogen occurs via E2F- and CHD8-mediated transcription of cyclin E2 downstream of cyclin D1, and does not require c-myc. PMID:19564413
23. Investigated downregulation of coronary vascular smooth muscle cell growth by siRNA against E2F1, cyclins E1 and E2. Data shows reduction in the phosphorylation levels of the retinoblastoma protein pRB and a decrease in the amount of cyclin A2. PMID:19603101
24. Loss of cyclin D1 in ovarian cancer cells treated with SHetA2 is sufficient to induce G(1) cell cycle arrest and this strategy is not impeded by the presence of cyclin E2. PMID:19638577

Show More

Hide All

HGNC: 1590

UNIGENE: Hs.521693

KEGG: hsa:9134

STRING: 9606.ENSP00000309181

OMIM: 603775